1 Einträge von mit factor immunglobulin
www.cslbehring.ch
Datum der Indexierung 04.10.2024 23:30:14
erkannte Namen Ria STAP | Norbert Heimberger | Asia Pacific |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description CSL Behring – a specialist in biotherapeutics for more than 100 years
Kombination Keywords behring more | first your | plasma plant | with award | approved approval | patients bern | treatment switzerland | factor immunglobulin | company rare | market production |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
factors in Lengnau. At least 300 new jobs will be created and, over a period of five years, an investment of over 400 million Swiss francs will be made. From 2019, three new recombinant coagulating factors will be produced and marketed around the wor immunglobulin (SCIg). In the U.S., Hizentra® is used to treat patients with primary immune deficiencies. Hizentra® is also undergoing the registration process for the EU and Switzerland. The immunglobulin product, which is stabili
Text Inhalt Text aus URL
Log Metriken 86083
erkannte Namen Ria STAP | Norbert Heimberger | Asia Pacific |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description CSL Behring – a specialist in biotherapeutics for more than 100 years
Kombination Keywords behring more | first your | plasma plant | with award | approved approval | patients bern | treatment switzerland | factor immunglobulin | company rare | market production |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
factors in Lengnau. At least 300 new jobs will be created and, over a period of five years, an investment of over 400 million Swiss francs will be made. From 2019, three new recombinant coagulating factors will be produced and marketed around the wor immunglobulin (SCIg). In the U.S., Hizentra® is used to treat patients with primary immune deficiencies. Hizentra® is also undergoing the registration process for the EU and Switzerland. The immunglobulin product, which is stabili
Text Inhalt Text aus URL
Log Metriken 86083